<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03781791</url>
  </required_header>
  <id_info>
    <org_study_id>ENT-01-030</org_study_id>
    <nct_id>NCT03781791</nct_id>
  </id_info>
  <brief_title>Orally Administered ENT-01 for Parkinson's Disease-Related Constipation (KARMET)</brief_title>
  <acronym>KARMET</acronym>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate Safety, Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease-Related Constipation (KARMET)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Enterin Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Enterin Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted as a multi-center, randomized, double-blind, placebo-controlled&#xD;
      study. Approximately 72 patients will be randomized 3:1 to treatment or placebo, with&#xD;
      approximately 54 patients allocated to receive the active investigational product and&#xD;
      approximately 18 patients allocated to receive placebo.&#xD;
&#xD;
      - Study Update-&#xD;
&#xD;
      Amendment 3 - In this amendment, an additional 80 patients (approximately) will be randomized&#xD;
      1:1 to treatment or placebo (double-blind) with approximately 40 subjects allocated to each&#xD;
      group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted on an out-patient basis. Each patient will have 6 visits to the&#xD;
      clinic: a screening visit, a randomization visit, 3 follow up visits, and 1 end of study&#xD;
      visit.&#xD;
&#xD;
      Patient randomization will be stratified based upon the baseline weekly complete spontaneous&#xD;
      bowel movement rate (CSBM) established during the screening period. Patients will be allowed&#xD;
      to adjust their dosing, based upon protocol specifications. Rescue medications will be&#xD;
      provided to all patients to ensure they move their bowels on a regular basis.&#xD;
&#xD;
      Patients will also be asked to participate in up to 2 sub-studies: a pk study and/or a stool&#xD;
      microbiome study. The first 20 patients to consent to the pk study will have additional blood&#xD;
      samples taken at randomization and at 2 follow up visits. The first 20 patients to consent to&#xD;
      the stool microbiome study will provide stool samples at randomization and at 2 follow up&#xD;
      visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 10, 2018</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment Related Adverse Events-Safety Endpoint</measure>
    <time_frame>Through Study treatment up to 10 weeks</time_frame>
    <description>The number of treatment related adverse events as reported and assessed by NCI CTCAE v.4.3.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment Related Adverse Event-Tolerability Endpoints</measure>
    <time_frame>Through Study treatment Dosing Period up to 10 weeks</time_frame>
    <description>The number of treatment related adverse events as reported and assessed by NCI CTCAE v.4.3.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in baseline weekly CSBM-Primary Efficacy Endpoint</measure>
    <time_frame>Through Study Treatment Dosing Period up to 10 weeks</time_frame>
    <description>Change from participant's weekly CSBM baseline rate during treatment fixed Dose period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in participant constipation severity from baseline-Secondary Efficacy Endpoints</measure>
    <time_frame>Through Study Treatment Dosing Period up to 10 weeks</time_frame>
    <description>Participant reported change from baseline as assessed according to Bristol Stool rating scale (0-5) of increasing severity of ease of bowel evacuation.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in baseline stool Microbiome - Exploratory Outcome</measure>
    <time_frame>Through Study Treatment Dosing Period and Completion up to 24 weeks</time_frame>
    <description>Collection of participant baseline intestinal microbiome condition as observed in stool to on treatment related effect of ENT-01 on stool microbiome</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">152</enrollment>
  <condition>Constipation</condition>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Active Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ENT-01 tablet will be taken once daily by mouth.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet will be taken once daily by mouth.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active Investigational Treatment ENT-01</intervention_name>
    <description>ENT-01 will be administered in tablet form, once daily.</description>
    <arm_group_label>Active Treatment</arm_group_label>
    <other_name>ENT-01</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Treatment</intervention_name>
    <description>Placebo will be administered in tablet form, once daily.</description>
    <arm_group_label>Placebo Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects aged 30-90 years, both genders&#xD;
&#xD;
          2. Subjects must provide written informed consent and be willing and able to comply with&#xD;
             study procedures.&#xD;
&#xD;
          3. Subjects must be diagnosed with Parkinson's Disease defined as the presence of at&#xD;
             least three of the following cardinal features, in the absence of alternative&#xD;
             explanations or atypical features: rest tremor, rigidity, bradykinesia and/or&#xD;
             akinesia, postural and gait abnormalities.&#xD;
&#xD;
          4. There are insufficient criteria for Irritable Bowel Syndrome (IBS)&#xD;
&#xD;
          5. Constipation which has been present for over 6 months and is unresponsive to first&#xD;
             line, typically over the counter treatments such as Milk of Magnesia (1g), Miralax&#xD;
             (17g in 8 ounces of water) or the equivalent at least once weekly with an inconsistent&#xD;
             response over a 6-week period or the subject is dissatisfied with first line&#xD;
             treatments.&#xD;
&#xD;
          6. Body mass index (BMI) of 18-40 kg/m2&#xD;
&#xD;
          7. Subjects must fulfill Rome IV criteria for functional constipation which includes 2 or&#xD;
             more of the following:&#xD;
&#xD;
               1. Straining during at least 25% of defecations&#xD;
&#xD;
               2. Lumpy or hard stools in at least 25% of defecations&#xD;
&#xD;
               3. Sensation of incomplete evacuation for at least 25% of defecations&#xD;
&#xD;
               4. Sensation of anorectal obstruction/blockage for at least 25% of defecations&#xD;
&#xD;
               5. Manual maneuvers to facilitate at least 25% of defecations (e.g., digital&#xD;
                  evacuation, support of the pelvic floor)&#xD;
&#xD;
          8. Self-report of fewer than 3 complete spontaneous bowel movements per week&#xD;
&#xD;
          9. Loose stools are rarely present without the use of laxatives&#xD;
&#xD;
         10. Subjects must be able to read, understand, and accurately record data into the diary&#xD;
             to guarantee full participation in the study.&#xD;
&#xD;
         11. Female subjects must have negative serum or urine pregnancy tests and must not be&#xD;
             lactating. For females able to bear children, a hormonal (i.e., oral, implantable, or&#xD;
             injectable) and single-barrier method, or a double-barrier method of birth control&#xD;
             must be used throughout the study. A vasectomized partner will be allowed as one in&#xD;
             conjunction with another single-barrier method.&#xD;
&#xD;
         12. Female subjects unable to bear children must have this documented in the CRF (i.e.,&#xD;
             tubal ligation, hysterectomy, or postmenopausal [defined as a minimum of one year&#xD;
             since the last menstrual period]). Post-menopausal status will be confirmed by&#xD;
             follicle stimulating hormone (FSH) in women less than 60 years of age.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unable or unwilling to provide informed consent or to comply with study procedures.&#xD;
&#xD;
          2. Diagnosis of secondary constipation beyond that of Parkinson's Disease&#xD;
&#xD;
          3. Review of Screening Diaries indicates fewer than 11 days of diary completion and/or 3&#xD;
             or more complete spontaneous bowel movements (CSBM) per week based upon the average&#xD;
             CSBM rate reported during the Screening Period&#xD;
&#xD;
          4. A compromised gastrointestinal system which includes:&#xD;
&#xD;
               1. Structural, metabolic, or functional GI diseases or disorders&#xD;
&#xD;
               2. Acute GI illness within 2 weeks of the screening visit&#xD;
&#xD;
               3. History of major GI surgery within 30 days of the screening visit (a history of&#xD;
                  cholecystectomy, polypectomy, hernia repair or appendicectomy are not&#xD;
                  exclusionary as long as they were performed more than 30 days before the&#xD;
                  screening visit)&#xD;
&#xD;
          5. Unable or unwilling to withdraw from laxatives, opiates, clonazepam, or any&#xD;
             medications which may cause constipation, 2 weeks prior to the dose adjustment period&#xD;
             and throughout the rest of the study.&#xD;
&#xD;
          6. Unable or unwilling to withdraw from proton pump inhibitors and antacids at the end of&#xD;
             the screening period.&#xD;
&#xD;
          7. Unable or unwilling to withdraw from pimavanserin during the study.&#xD;
&#xD;
          8. Any clinically significant abnormalities on screening laboratories or physical&#xD;
             examination requiring further evaluation or treatment.&#xD;
&#xD;
          9. Neurological disorder other than Parkinson's Disease that in the opinion of the&#xD;
             investigator might interfere with the conduct of the study.&#xD;
&#xD;
         10. On treatment with intra-jejunal dopamine or carbidopa/levodopa (i.e. Duopa).&#xD;
&#xD;
         11. Subjects starting a new Parkinson's Disease medication or modifying an existing&#xD;
             medication within 2 weeks prior to enrollment.&#xD;
&#xD;
         12. Unable to maintain a stable diet regimen.&#xD;
&#xD;
         13. Subjects with a cognitive impairment that preclude them from understanding the&#xD;
             informed consent.&#xD;
&#xD;
         14. Subjects placed under legal guardianship.&#xD;
&#xD;
         15. Females who are pregnant or breastfeeding.&#xD;
&#xD;
         16. History of excessive alcohol use or substance abuse.&#xD;
&#xD;
         17. Participation in an investigational drug trial within the month prior to dosing in the&#xD;
             present study.&#xD;
&#xD;
         18. Any other reason, which, in the opinion of the investigator, would confound proper&#xD;
             interpretation of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Zasloff, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Enterin Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Denise Barbut, MD, FRCP</last_name>
    <role>Study Director</role>
    <affiliation>Enterin Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Denise Barbut, MD, FRCP</last_name>
    <phone>215 634 9243</phone>
    <email>KARMETinfo@enterininc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Banner Sun Health Research Institute</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trials, Inc.</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>The Parkinson's and Movement Disorder Institute</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivia Tong</last_name>
      <phone>714-378-5033</phone>
      <email>olivia@pmdi.org</email>
    </contact>
    <contact_backup>
      <last_name>Rachel Romansik</last_name>
      <phone>714-378-5033</phone>
      <email>rr@pmdi.org</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel D. Truong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neuro Pain Medical Center</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Perminder Bhatia, MD</last_name>
      <phone>559-437-9700</phone>
      <email>BHATIA@neuropain.com</email>
    </contact>
    <investigator>
      <last_name>Perminder Bhatia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Baker, PAC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pacific Neuroscience Medical Group</name>
      <address>
        <city>Oxnard</city>
        <state>California</state>
        <zip>93030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>SC3 Research - Pasadena</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ngoc Nguyen</last_name>
      <phone>626-250-2070</phone>
      <phone_ext>738</phone_ext>
      <email>ngoc.nguyen@neurosearch-usa.com</email>
    </contact>
    <contact_backup>
      <last_name>Brakail Franklin</last_name>
      <phone>6262502070</phone>
      <phone_ext>739</phone_ext>
      <email>brakail.franklin@neurosearch-usa.com</email>
    </contact_backup>
    <investigator>
      <last_name>Richard Shubin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathan J Eskenazi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>M. Lorraine Purino, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Carr, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Deborah L Leong, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ngoc Nguyen</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brakail Franklin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gregory Park</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wayne Pickerell</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Trial Connections - Care Access Research, Santa Clarita</name>
      <address>
        <city>Santa Clarita</city>
        <state>California</state>
        <zip>91321</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Movement Disorders Center</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajeev Kumar, MD</last_name>
      <phone>303-357-5455</phone>
      <email>rajeev_kumar@msn.com</email>
    </contact>
    <investigator>
      <last_name>Victoria Segro</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sarah Robbins</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Beth Capozzi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jessica Jaynes</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Associated Neurologist of Southern CT</name>
      <address>
        <city>Fairfield</city>
        <state>Connecticut</state>
        <zip>06824</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Care Access Research, Norwich</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexis Ahmad</last_name>
      <phone>202-264-9290</phone>
      <email>asc73@georgetown.edu</email>
    </contact>
    <contact_backup>
      <last_name>Luke Lovelace</last_name>
      <email>ll928@georgetown.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Fernando Pagan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>JEM Research Institute</name>
      <address>
        <city>Atlantis</city>
        <state>Florida</state>
        <zip>33462</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Goldstein, MD</last_name>
      <phone>561-968-2933</phone>
    </contact>
    <investigator>
      <last_name>Eric Kramer</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Casandra Mateo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elizabeth Sheldon</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mara Bailey</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Lisa Curtis</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Parkinson's Disease and Movement Disorders Center of Boca Raton</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Elias Research - Floridian Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33145</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Elias Research - Allied Biomedical Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Pharmax Research of South Florida</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>MEDSOL Clinical Research</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33952</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Parkinson's Disease Treatment Center of SWFL</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33980</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramon Gil, MD</last_name>
      <phone>941-743-4987</phone>
      <email>gilramon@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Sally Thimn</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Intercoastal Medical Group</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeanette Wilson, RN</last_name>
      <phone>941-203-3750</phone>
      <email>jewilson@intercoastalmedical.com</email>
    </contact>
    <investigator>
      <last_name>Ricardo Gonzalez, MD, DDS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mauricio Concha, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kelly Brown</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeanette Wilson, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarasota Memorial Hospital</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leigh Harrell</last_name>
      <phone>813-396-0768</phone>
      <email>leighharrell@health.usf.edu</email>
    </contact>
    <investigator>
      <last_name>Robert A. Hauser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Deborah A. Burke, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kelly Hussey, PA-C</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leigh Harrell, CCRC, CRA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Palm Beach Neurology and Premier Research Institute</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tom Voulgaris</last_name>
      <phone>561-296-3854</phone>
      <email>t.voulgaris@palmbeachneurology.com</email>
    </contact>
    <investigator>
      <last_name>Nisha Chhabria, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlanta Center for Medical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>BTC Network - Community Clinical Research Center</name>
      <address>
        <city>Anderson</city>
        <state>Indiana</state>
        <zip>46011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Interspond - The Neuromedical Clinic of Central Louisiana</name>
      <address>
        <city>Alexandria</city>
        <state>Louisiana</state>
        <zip>71301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>The NeuroMedical Center, P.C.</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70810</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Parkinson's and Movement Disorders Center of Maryland</name>
      <address>
        <city>Elkridge</city>
        <state>Maryland</state>
        <zip>21075</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford West Bloomfield Hospital</name>
      <address>
        <city>West Bloomfield</city>
        <state>Michigan</state>
        <zip>48322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Neurology Associates Clinical Research</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Interspond - Neurology Center of Las Vegas</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>13756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aboubacar Cherif</last_name>
      <phone>603-650-4506</phone>
      <email>Aboubacar.Cherif@hitchcock.org</email>
    </contact>
    <investigator>
      <last_name>Feldman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Evolution Research Group - Neuroscience Research Institution</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Brocco</last_name>
      <phone>732-341-9500</phone>
      <email>abrocco@amrinj.com</email>
    </contact>
    <investigator>
      <last_name>Rocco DiPaola, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sanjiv Sharma, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neuroscience Researc Institute of NJ</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rocco DiPaola, MD</last_name>
      <phone>732-447-6834</phone>
      <email>rocandcar@optonline.net</email>
    </contact>
    <investigator>
      <last_name>Sanjiv Sharma</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albany Medical College</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Czerwinski, RN</last_name>
      <phone>518-262-0034</phone>
      <email>czerwim@amc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sharon Evans, LPN</last_name>
      <email>evanss@amc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Eric Molho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Octavian Adam, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mindy Lopez</last_name>
      <phone>212-241-9038</phone>
      <email>mindy.lopez1@mssm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Christina Rosario</last_name>
      <email>Christina.rosario@mssm.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Winona Tse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Raleigh Neurology Associates</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Medical Center</name>
      <address>
        <city>Wake Forest</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Dayton Center for Neurological Disorders</name>
      <address>
        <city>Centerville</city>
        <state>Ohio</state>
        <zip>45459</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Erin Neefus, BS CCRP</last_name>
      <phone>513-558-6555</phone>
      <email>erin.neefus@uc.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew Duker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Beth Serrano</last_name>
      <phone>216-636-0835</phone>
      <email>serranm2@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Benjamin Walter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Elias Research - Neurology Diagnostics Research</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45459</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Toledo Medical Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Spears, CCRC</last_name>
      <phone>419-383-6728</phone>
      <email>julia.spears@utoledo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Stephanie Wilson, MSN APRN</last_name>
      <phone>4193836721</phone>
      <email>stephanie.wilson@utoledo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Lawrence Elmer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julia Spears, CCRC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mary E. Scott</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nancy Vollmar</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Movement Disorder Clinic of Oklahoma</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Penn State University</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bryan Mullen</last_name>
      <phone>717-425-0419</phone>
      <email>bmullen1@pennstatehealth.psu.edu</email>
    </contact>
    <investigator>
      <last_name>Thyagarajan Subramanian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Interspond - Premier Neurology</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29650</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Interspond - Metrolina Neurological Associates</name>
      <address>
        <city>Indian Land</city>
        <state>South Carolina</state>
        <zip>29707</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>North Texas Movement Disorders Institute</name>
      <address>
        <city>Bedford</city>
        <state>Texas</state>
        <zip>76021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>BTC Network - Neurological Associates of North Texas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Network</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Sentara Neuroscience Institute</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23456</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Evergreen Health - Booth Gardner Parkinson's Care Center</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anhaita Jamula</last_name>
      <phone>425-899-5372</phone>
      <email>acjamula@evergreenhealth.com</email>
    </contact>
    <investigator>
      <last_name>Daniel Burdick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Physicians &amp; Surgeons, Inc. dba Marshall Health</name>
      <address>
        <city>Huntington</city>
        <state>West Virginia</state>
        <zip>25701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Runyon, RN</last_name>
      <phone>304-691-6859</phone>
      <email>ross35@marshall.edu</email>
    </contact>
    <contact_backup>
      <last_name>Alexis N. Damron, MSN/Ed RN</last_name>
      <phone>3046916432</phone>
      <phone_ext>6432</phone_ext>
      <email>damrona@marshall.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Vikram Shivkumar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul Ferguson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 27, 2018</study_first_submitted>
  <study_first_submitted_qc>December 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 20, 2018</study_first_posted>
  <last_update_submitted>January 5, 2021</last_update_submitted>
  <last_update_submitted_qc>January 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

